Marine ω-3 Fatty Acid Intake

Associations with cardiometabolic risk and response to weight loss intervention in the Look AHEAD (Action for Health in Diabetes) study

L. MARIA BELALCAZAR, MD 1
DAVID M. REBOUSSIN, PhD 2
STEVEN M. HAFFNER, MD 3
REBECCA S. REEVES, DrPH 4
DAWN C. SCHWENKE, PhD 5
RON C. HOOGVEEN, PhD 6
F. XAVIER PI-SUNYER, MD 6
CHRISTIE M. BALLANTYNE, MD 4, 7

FOR THE LOOK AHEAD (ACTION FOR HEALTH IN DIABETES) OBESITY, INFLAMMATION, AND THROMBOSIS RESEARCH GROUP*

OBJECTIVE — To examine usual marine ω-3 fatty acid (mO-3FA) intake in individuals with diabetes; its association with adiposity, lipid, and glucose control; and its changes with behavioral lifestyle intervention for weight loss.

RESEARCH DESIGN AND METHODS — Cross-sectional and 1-year longitudinal analyses were performed on 2,397 Look AHEAD (Action for Health in Diabetes) participants. Look AHEAD is a cardiovascular outcome trial evaluating the effects of intensive lifestyle intervention for weight loss in overweight/obese subjects with type 2 diabetes.

RESULTS — Baseline mO-3FA intake was 162 ± 138 mg/day. It was inversely associated with triglycerides (β = −0.41, P < 0.001) and weakly with HDL (β = 0.14, P = 0.050), after multiple covariate adjustment. One-year mO-3FA and fried/sandwich fish intake decreased with intensive lifestyle intervention (P < 0.001).

CONCLUSIONS — mO-3FA intake in Look AHEAD participants was low but associated favorably with lipids. These results encourage investigation on the potential benefits of increasing mO-3FA intake in lifestyle interventions for weight loss in individuals with diabetes.

Diabetes Care 33:197–199, 2010

Observational studies have suggested that marine ω-3 fatty acid (mO-3FA) intake may decrease coronary atherosclerosis progression in subjects with diabetes (1). However, only a fraction of participants in cardiovascular event studies have had diabetes. Concerns that high-dose mO-3FAs may worsen glucose control have reduced enthusiasm for their use in diabetes (2). Little is known regarding usual dietary mO-3FA intake and its association with metabolic disturbances in diabetes, and much less is known about the effects of weight loss interventions on mO-3FA consumption.

RESEARCH DESIGN AND METHODS — A total of 2,397 participants, corresponding to the first half of Look AHEAD (Action for Health in Diabetes) enrollees, completed the Look AHEAD food frequency questionnaire (LA-FFQ) (3). Look AHEAD is a multicenter randomized trial in overweight/obese individuals with type 2 diabetes, investigating the effects of intensive lifestyle intervention–induced weight loss on cardiovascular morbidity and mortality. Eligibility criteria included BMI ≥25 kg/m² (≥27 kg/m² if on insulin), age 45–76 years, A1C <11%, blood pressure ≤160/100 mmHg, and fasting triglycerides ≤600 mg/dl (4).

The LA-FFQ and its analysis were previously described (3). Eight line items inquire about seafood consumption. mO-3FA intake was estimated by adding eicosapentaenoic acid and docosahexaenoic acid intake from the LA-FFQ.

Statistical analysis

The baseline association between mO-3FA intake and weight, BMI, waist circumference, A1C, fasting glucose, and lipids was examined using multiple-variable linear regression. The final model included demographics, dietary variables, fitness (exercise capacity on graded exercise test), and class use of medications to control lipids and glucose. Comparisons between race/ethnicity groups were tested with ANCOVA. Differences in variable change at 1 year between intensive lifestyle intervention and the usual-care group (diabetes, support, and education) were analyzed with an unpaired t test and χ² test. Data were available for each variable analyzed in ≥99% of participants. An α < 0.05 indicated significance.

RESULTS — Participant baseline characteristics do not differ from those of the overall Look AHEAD sample (5) with respect to sex, race/ethnicity, adiposity, or fitness. Age criteria change during the second year of study recruitment resulted in a slightly younger age in our subgroup (see Table S1, available in an online appendix at http://care.diabetesjournals.org/cgi/content/full/dc09-1235/DC1).

mO-3FA intake and metabolic variables at baseline

Mean mO-3FA intake was 162 ± 138 mg/day (median 120 mg/day). Intake was ≥200 mg/day in 75% of Look AHEAD
Marine ω-3 fatty acid intake in Look AHEAD

Table 1—Dietary intake of mO-3FAs and fried fish and HDL and triglyceride levels at baseline and 1 year

|                  | mO-3FA (mg/day) | HDL (mg/dl) | Triglycerides (mg/dl) | Subjects with fried fish/sandwich fish intake ≥1/week (%) |
|------------------|-----------------|-------------|----------------------|----------------------------------------------------------|
| Baseline         |                 |             |                      |                                                          |
| Overall (n = 2,397) | 162 (138)      | 43 (11.3)   | 186 (125.6)          |                                                          |
| African American (n = 331) | 205 (186)*     | 48.2 (13.0)*| 127.4 (99.8)*        |                                                          |
| Caucasian (n = 1,552) | 160 (130)      | 41.4 (10.7) | 197.6 (127.01)       |                                                          |
| Other (n = 76)    | 156 (117)       | 45.0 (12.1) | 156.7 (90.7)         |                                                          |
| Hispanic (n = 316) | 152 (115)       | 42.4 (10.8) | 191.7 (119.7)        |                                                          |
| Native American (n = 122) | 98 (117)      | 40.9 (9.0)  | 192.7 (156.1)        |                                                          |
| Longitudinal     |                 |             |                      |                                                          |
| IIL (n = 1,211)   |                 |             |                      |                                                          |
| Baseline         | 160 (145)       | 43 (11.2)   | 189 (127.4)          | 5.62                                                     |
| Change at 1 year |                 |             |                      |                                                          |
| DSE (n = 1,186)   |                 |             |                      |                                                          |
| Baseline         | 160 (129)       | 42 (11.3)   | 182 (123.6)          | 6.16                                                     |
| Change at 1 year |                 |             |                      |                                                          |

*Differences across race/ethnicity groups were tested by ANOVA after adjusting for age, sex, and clinic site.

|                  | Change at 1 year | Statistic | P       |
|------------------|------------------|-----------|---------|
| Caucasian        | -20 (137)†       | 3.5 (7.1)†| 0.050   |
| Hispanic         | -34.9 (11.5)‡    | -3.56‡    | 0.012‡  |
| Native American  | 0 (121)          | 1.4 (6.6) | 0.93    |

Participants and ≥1,000 mg/day in only 1%, with significant race/ethnicity differences (Table 1). mO-3FA intake was inversely associated with triglycerides (log-transformed) (β = -0.41, P < 0.001) and with a trend for increasing HDL (β = 4.14, P = 0.050), independently of multiple covariates (Table S2). No association was found between mO-3FA intake and each of cholesterol, non-HDL or LDL cholesterol, markers of adiposity, or glucose control (P > 0.05). African Americans, who consumed the most mO-3FAs, had the highest HDL cholesterol and the lowest triglycerides.

mO-3FA intake and HDL and triglyceride levels with intensive lifestyle intervention at 1 year

mO-3FA intake decreased with intensive lifestyle intervention but not with diabetes, support, and education at 1 year (P < 0.001) (Table 1). When investigating changes in type of fish consumed, we found an intensive lifestyle intervention-induced decrease in fried/sandwich fish consumption (P < 0.001) but not in lean or mO-3FA–rich fish. The small change in mO-3FA intake with intensive lifestyle intervention did not explain 1-year changes in HDL and triglycerides.

CONCLUSIONS—Look AHEAD offers a large sample of individuals with diabetes in whom a validated tool was used to estimate usual mO-3FA intake. mO-3FA consumption was found to be very low. An intake of ≥1,000 mg/day is recommended for people with diabetes (6–8). Despite the low levels, mO-3FA consumption was associated with lower triglycerides and with a trend for higher HDL. The relationship between mO-3FAs and each of HDL and triglycerides was independent of adiposity, fitness, lipid medications (including fibrates), glycemic control, and dietary variables that affect lipid levels, such as carbohydrate, fiber, and saturated fat. Likewise, the intake of linoleic acid, a precursor of eicosapentaenoic acid and docosahexaenoic acid, and consumption of its metabolic competitor linoleic acid, did not alter the relationship between mO-3FA intake and HDL and triglycerides.

Contrary to reports with high-dose mO-3FA (9,10), we did not find an unfavorable association between mO-3FA consumption and LDL cholesterol or glucose control. These findings encourage future outcome studies in individuals with diabetes evaluating lower intakes of mO-3FA than those previously investigated. A large trial with eicosapentaenoic acid supplementation in high-risk subjects found the greatest reduction in cardiovascular events in the subgroup with lower HDL and higher triglycerides (11), raising the possibility that mO-3FA may be of a particular benefit in individuals with diabetes, who characteristically display this lipid profile. The race/ethnicity differences in mO-3FA consumption and the question of whether specific groups might specifically benefit from interventions that increase mO-3FA intake are worthy of further study.

The decrease in mO-3FAs with intensive lifestyle intervention is not surprising given that the Look AHEAD intervention was not targeted at increasing mO-3FA intake. The decrease in mO-3FA intake paralleled a reduction in fried/sandwich fish intake, which is considered favorable (12).

Our results should be interpreted with caution. Look AHEAD did not evaluate supplement use and is subject to the limitations of information obtained by self-report (3). The favorable association between usual dietary mO-3FA intake and lipids at baseline encourages future research on the potential benefit of increasing consumption of mO-3FAs, in addition to modifying fish type, when planning lifestyle interventions for weight loss in individuals with diabetes.

Acknowledgments—This study was supported by the National Heart, Lung, and Blood Institute Grants 3R01 HL090514-02S1 (to L.M.B.) and HL090514 (to C.M.B.). The Look AHEAD study is sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases and cosponsored by the National Heart, Lung and Blood Institute, the National Institute of Nursing Research, the Office of Research on Women’s Health, the National Center on Minority Health and Health Disparities, and the Centers for Disease Control and Prevention. A complete list of contributors and resource centers may be found in Ref. 5.

D.C.S. has received research support from Takeda Pharmaceuticals. C.M.B. has acted as a consultant to and speaker for GlaxoSmithKline. No other potential conflicts of interest relevant to this article were reported.

Parts of this study were presented in abstract form at the 69th Scientific Sessions of the American Diabetes Association, New Orleans, Louisiana, 5–9 June 2009.
APPENDIX — Members of the Look AHEAD Obesity, Inflammation, and Thrombosis Research Group include Christie M. Ballantyne, MD; L. Maria Belalcazar, MD; Elaine S. Cornell, BS; Steven F. Haffner, MD; Ron C. Hoogeveen, PhD; Andrea Kriska, PhD; Santica M. Marcovina, PhD; Elizabeth Mayer-Davis, PhD; F. Xavier Pi-Sunyer, MD; David M. Reboussin, PhD; Rebecca S. Reeves, DrPh; Charles E. Rhodes, BS; Dawn C. Schwenke, PhD; and Russell P. Tracy, PhD.

References

1. Erkkila AT, Lichtenstein AH, Mozaffarian D, Herrington DM. Fish intake is associated with a reduced progression of coronary artery atherosclerosis in postmenopausal women with coronary artery disease. Am J Clin Nutr 2004;80:626–632
2. Glauber H, Wallace P, Griver K, Brechtle G. Adverse metabolic effect of omega-3 fatty acids in non-insulin-dependent diabetes mellitus. Ann Intern Med 1988;108:663–668
3. Vitolins MZ, Anderson AM, Delahanty L, Raynor H, Miller GD, Mobley C, Reeves R, Yamamoto M, Champagne C, Wing RR, Mayer-Davis E; Look AHEAD Research Group. Action for Health in Diabetes (Look AHEAD) trial: baseline evaluation of selected nutrients and food group intake. J Am Diet Assoc 2009;109:1367–1375
4. Ryan DH, Espeland MA, Foster GD, Haffner SM, Hubbard VS, Johnson KC, Kahn SE, Knowler WC, Yanovski SZ. Look AHEAD Research Group. Look AHEAD (Action for Health in Diabetess): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes. Control Clin Trials 2003;24:610–628
5. Look AHEAD Research Group, Pi-Sunyer X, Blackburn G, Brancati FL, Bray GA, Bright R, Clark JM, Curtis JM, Espeland MA, Foreyt JP, Graves K, Haffner SM, Harrison B, Hill JO, Horton ES, Jakicic J, Jeffery RW, Johnson KC, Kahn S, Kelley DE, Kitabchi AE, Knowler WC, Lewis CE, Maschak-Carey BJ, Montgomery B, Nathan DM, Patricio J, Peters A, Redmon JB, Reeves RS, Ryan DH, Safford M, Van Dorsten B, Wadden TA, Wagenknecht L, Wesche-Thobaben J, Wing RR, Yanovski SZ. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the Look AHEAD trial. Diabetes Care 2007;30:1374–1383
6. American Diabetes Association. Standards of medical care in diabetes: 2009. Diabetes Care 2009;32:S13–S61
7. Franz MJ. 2002 diabetes nutrition recommendations: grading the evidence. Diabetes Educ 2002;28:756–779, 762–764, 766
8. Lichtenstein AH, Appel LJ, Brands M, Carnethon M, Daniels S, Franch HA, Franklin B, Kris-Etherton P, Harris WS, Howard B, Karanja N, Lefevre M, Rudel L, Sacks F, Van Horn L, Winston M, Wylie-Rosett J. Summary of American Heart Association Diet and Lifestyle Recommendations revision 2006. Arterioscler Thromb Vasc Biol 2006;26:2186–2191
9. Hu FB, Cho E, Rexrode KM, Albert CM, Manson JE. Fish and long-chain omega-3 fatty acid intake and risk of coronary heart disease and total mortality in diabetic women. Circulation 2003;107:1852–1857
10. Harris WS. n-3 fatty acids and serum lipoproteins: human studies. Am J Clin Nutr 1997;65(Suppl. 5):1645S–1654S
11. Saito Y, Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K; the JELIS Investigators, Japan. Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis 2008;200:135–140
12. Mozaffarian D, Lemaitre RN, Kuller LH, Burke GL, Tracy RP, Siscovick DS, the Cardiovascular Health Study. Cardiac benefits of fish consumption may depend on the type of fish meal consumed: the Cardiovascular Health Study. Circulation 2003;107:1372–1377